PubMed laboratory research record [PMID: 36003674] PubMed record related to this compound for laboratory literature review
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly GLP1 2.4 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial
Published patent applications are not granted patents
Liver fibrosis represents, together with the comorbidities of metabolic syndrome, a significant prognostic determinant in NAFLD
Strode C, Wondji CS, David J-P, Hawkes NJ, Lumjuan N, Nelson DR
That quickly led to more drugs including Novo Nordisks WeGovy, FDA approved to treat obesity in 2121